The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

EGFR-mutant lung cancers develop a wide range of potential resistance alterations under therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET amplification ranks among the most common acquired resistance alterations and is currently being investigated as a therapeutic tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Jóri, Balázs, Vössing, Christine, Pirngruber, Judith, Willing, Eva Maria, Arndt, Kathrin, Falk, Markus, Tiemann, Markus, Heukamp, Lukas C., Hoffknecht, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605877/
https://www.ncbi.nlm.nih.gov/pubmed/37887535
http://dx.doi.org/10.3390/curroncol30100635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605877/
https://www.ncbi.nlm.nih.gov/pubmed/37887535
http://dx.doi.org/10.3390/curroncol30100635

Ejemplares similares